Rohatiner A, Slevin M L, Dhaliwal H S, Malpas J S, Lister T A
Cancer Chemother Pharmacol. 1984;12(2):90-3. doi: 10.1007/BF00254596.
Twenty-six patients with acute leukaemia and 14 with high-grade lymphoma received cytosine arabinoside (ara-C) at a twice daily dose of 2 g/m2 administered as a 3-h infusion. Thirty-four patients received 12 doses and six electively received four doses only. Complete remission was achieved in six of seven patients with acute myelogenous leukaemia (AML), one of two evaluable patients with blast crisis of chronic myeloid leukaemia and three of eight patients with acute lymphoblastic leukaemia (ALL). Three further patients with ALL had only minimal bone marrow infiltration after one cycle, toxicity precluding administration of a second. Three patients with AML who received four doses only showed no evidence of response. Four of 14 patients with lymphoma who received 12 doses, entered complete remission. Five additional patients died with minimal residual disease whilst severely neutropenic. A complete and a partial response were seen in two patients with immunoblastic and centrocytic lymphoma respectively who received four doses. These results confirm the activity of high-dose ara-C in patients with AML and suggest that it may also be a potentially useful agent in ALL and high-grade lymphoma, especially as the incidence of CNS toxicity is lower than that reported at higher doses.
26例急性白血病患者和14例高级别淋巴瘤患者接受了阿糖胞苷（ara-C）治疗，每日两次给药，剂量为2 g/m²，静脉滴注3小时。34例患者接受了12次剂量治疗，6例患者仅选择性地接受了4次剂量治疗。7例急性髓系白血病（AML）患者中有6例达到完全缓解，2例可评估的慢性髓系白血病急变期患者中有1例达到完全缓解，8例急性淋巴细胞白血病（ALL）患者中有3例达到完全缓解。另有3例ALL患者在一个疗程后仅有轻微骨髓浸润，因毒性无法进行第二个疗程治疗。仅接受4次剂量治疗的3例AML患者未显示出缓解迹象。14例接受12次剂量治疗的淋巴瘤患者中有4例达到完全缓解。另外5例患者在严重中性粒细胞减少且残留疾病极少的情况下死亡。分别接受4次剂量治疗的2例免疫母细胞淋巴瘤和中心细胞淋巴瘤患者出现了完全缓解和部分缓解。这些结果证实了大剂量阿糖胞苷对AML患者的疗效，并表明它在ALL和高级别淋巴瘤中也可能是一种潜在的有效药物，尤其是中枢神经系统毒性的发生率低于高剂量时报道的发生率。
